NNFN Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
MannKind Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.00 |
| 52 Week High | US$7.00 |
| 52 Week Low | US$3.79 |
| Beta | 1.14 |
| 1 Month Change | 1.01% |
| 3 Month Change | -21.81% |
| 1 Year Change | -4.03% |
| 3 Year Change | 20.36% |
| 5 Year Change | 182.09% |
| Change since IPO | -92.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| NNFN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.2% | -0.3% | 0.8% |
| 1Y | -4.0% | -12.7% | 14.6% |
Return vs Industry: NNFN exceeded the German Biotechs industry which returned -12.3% over the past year.
Return vs Market: NNFN underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| NNFN volatility | |
|---|---|
| NNFN Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: NNFN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NNFN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 405 | Michael Castagna | www.mannkindcorp.com |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus.
MannKind Corporation Fundamentals Summary
| NNFN fundamental statistics | |
|---|---|
| Market cap | €1.19b |
| Earnings (TTM) | €27.01m |
| Revenue (TTM) | €266.91m |
44.1x
P/E Ratio4.5x
P/S RatioIs NNFN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNFN income statement (TTM) | |
|---|---|
| Revenue | US$297.60m |
| Cost of Revenue | US$75.52m |
| Gross Profit | US$222.08m |
| Other Expenses | US$191.96m |
| Earnings | US$30.12m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.099 |
| Gross Margin | 74.62% |
| Net Profit Margin | 10.12% |
| Debt/Equity Ratio | -61.6% |
How did NNFN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 16:48 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MannKind Corporation is covered by 27 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |